ES2650247T3 - Procedimiento de preparación del bosentán - Google Patents

Procedimiento de preparación del bosentán Download PDF

Info

Publication number
ES2650247T3
ES2650247T3 ES09709282.9T ES09709282T ES2650247T3 ES 2650247 T3 ES2650247 T3 ES 2650247T3 ES 09709282 T ES09709282 T ES 09709282T ES 2650247 T3 ES2650247 T3 ES 2650247T3
Authority
ES
Spain
Prior art keywords
bosentan
preparation procedure
formula
compound
structural unit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09709282.9T
Other languages
English (en)
Inventor
Abhay Gaitonde
Bindu Manojkumar
Sandeep Mekde
Vikas Padalkar
Hemant Mande
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Generics UK Ltd
Original Assignee
Generics UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generics UK Ltd filed Critical Generics UK Ltd
Application granted granted Critical
Publication of ES2650247T3 publication Critical patent/ES2650247T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69—Benzenesulfonamido-pyrimidines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un procedimiento de preparación del bosentán usando un compuesto de fórmula (2a):**Fórmula** en la que R es una unidad estructural de protección de hidroxilo.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9

Claims (1)

  1. imagen1
    imagen2
    imagen3
ES09709282.9T 2008-02-08 2009-02-06 Procedimiento de preparación del bosentán Active ES2650247T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN228KO2008 2008-02-08
INKA02282008 2008-02-08
PCT/GB2009/050120 WO2009098517A1 (en) 2008-02-08 2009-02-06 Process for preparing bosentan

Publications (1)

Publication Number Publication Date
ES2650247T3 true ES2650247T3 (es) 2018-01-17

Family

ID=40467334

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09709282.9T Active ES2650247T3 (es) 2008-02-08 2009-02-06 Procedimiento de preparación del bosentán

Country Status (10)

Country Link
US (1) US8785461B2 (es)
EP (1) EP2245018B1 (es)
JP (1) JP5683276B2 (es)
CN (1) CN101939301B (es)
AU (1) AU2009211159B2 (es)
CA (1) CA2712860C (es)
ES (1) ES2650247T3 (es)
NZ (1) NZ587793A (es)
PT (1) PT2245018T (es)
WO (1) WO2009098517A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009004374A1 (en) 2007-06-29 2009-01-08 Generics [Uk] Limited Process for introduction of hydroxyethoxy side chain in bosentan
US8530488B2 (en) 2007-10-24 2013-09-10 Generics [Uk] Limited Crystalline forms of bosentan
EP2350028A1 (en) 2008-11-03 2011-08-03 Generics [UK] Limited Hplc method for the analysis of bosentan and related substances and use of these substances as reference standards and markers
WO2013098577A1 (en) * 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical compositions of bosentan
CN104487057A (zh) * 2012-05-11 2015-04-01 韩诺生物制药株式会社 波生坦控释口服制剂
CN112457259B (zh) * 2020-12-08 2024-02-20 重庆康乐制药有限公司 一种磺胺多辛的制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
US5739333A (en) * 1995-05-16 1998-04-14 Tanabe Seiyaku Co., Ltd. Sulfonamide derivative and process for preparing the same
US6136971A (en) * 1998-07-17 2000-10-24 Roche Colorado Corporation Preparation of sulfonamides
JP2003514798A (ja) 1999-11-17 2003-04-22 テバ ファーマシューティカル インダストリーズ リミティド アトルバスタチンカルシウムの多形
US6610718B2 (en) 1999-12-16 2003-08-26 Teva Pharmaceutical Industries Ltd. Processes for making- and a new crystalline form of- leflunomide
JP3751882B2 (ja) * 2000-01-25 2006-03-01 エフ．ホフマン−ラ ロシュ アーゲー スルホンアミドの製造
US6479692B1 (en) 2001-05-02 2002-11-12 Nobex Corporation Methods of synthesizing acylanilides including bicalutamide and derivatives thereof
WO2004076443A1 (en) 2003-02-25 2004-09-10 Hetero Drugs Limited Amorphous form of losartan potassium
WO2004081016A1 (en) 2003-03-12 2004-09-23 Cadila Healthcare Limited Polymorphs and amorphous form of (s) - (+) -clopidogrel bisulfate
WO2004087660A1 (en) 2003-04-02 2004-10-14 Hetero Drugs Limited A novel process for amorphous form of donepezil hydrochloride
ES2336943T3 (es) 2005-05-17 2010-04-19 Actelion Pharmaceuticals Ltd. Comprimido de bosentan dispersable.
US20080188663A1 (en) 2007-01-29 2008-08-07 Ashok Kumar Process for the preparation of crystalline clopidogrel hydrogen sulphate Form I
WO2008122020A1 (en) 2007-04-02 2008-10-09 Auspex Pharmaceuticals, Inc. Substituted pyrimidines
US8288401B2 (en) 2007-05-08 2012-10-16 Generics [Uk] Limited Polymorphic forms
WO2009004374A1 (en) 2007-06-29 2009-01-08 Generics [Uk] Limited Process for introduction of hydroxyethoxy side chain in bosentan
US20110014291A1 (en) 2007-10-11 2011-01-20 Actavis Group Ptc Ehf Novel Polymorphs of Bosentan
US8530488B2 (en) 2007-10-24 2013-09-10 Generics [Uk] Limited Crystalline forms of bosentan
ATE530531T1 (de) * 2007-12-18 2011-11-15 Dipharma Francis Srl Verfahren zur herstellung von bosentan
WO2009095933A2 (en) 2008-01-10 2009-08-06 Msn Laboratories Limited Improved and novel process for the preparation of bosentan
EP2240469A2 (en) 2008-01-24 2010-10-20 Actavis Group PTC EHF Substantially pure and a stable crystalline form of bosentan
EP2268634A2 (en) 2008-03-13 2011-01-05 Actavis Group PTC EHF Processes for the preparation of bosentan and related compounds using novel intermediates
EP2294056A1 (en) * 2008-05-23 2011-03-16 Synthon B.V. Bosentan salts
EP2350028A1 (en) 2008-11-03 2011-08-03 Generics [UK] Limited Hplc method for the analysis of bosentan and related substances and use of these substances as reference standards and markers
IT1393136B1 (it) 2009-03-11 2012-04-11 Sifa Vitor S R L Procedimento per la preparazione del bosentan

Also Published As

Publication number Publication date
PT2245018T (pt) 2017-12-05
EP2245018A1 (en) 2010-11-03
US8785461B2 (en) 2014-07-22
AU2009211159A1 (en) 2009-08-13
JP5683276B2 (ja) 2015-03-11
AU2009211159B2 (en) 2013-02-07
JP2011511054A (ja) 2011-04-07
CN101939301B (zh) 2016-07-06
CA2712860A1 (en) 2009-08-13
CA2712860C (en) 2014-11-18
US20110039871A1 (en) 2011-02-17
WO2009098517A1 (en) 2009-08-13
CN101939301A (zh) 2011-01-05
NZ587793A (en) 2012-06-29
EP2245018B1 (en) 2017-08-30

Similar Documents

Publication Publication Date Title
ES2650247T3 (es) Procedimiento de preparación del bosentán
ES2634490T3 (es) Derivados de ácido napht-2-ylacetico para tratar el sida
ES2574912T3 (es) Procedimiento para obtener lignina
ES2525481T3 (es) Derivados espirocíclicos de ácido tetrónico
AR112532A2 (es) Compuestos de tetraciclina sustituidos con flúor en c7
CL2011002115A1 (es) Compuestos derivados de 5-fenil-1h-piridin-2-ona y 5-fenil-pirazin-2-ona, inhibidores de la tirosina-quinasa de bruton (btk); proceso de preparación de los compuestos, compuesto intermediario, composición farmacéutica y uso en el tratamiento de enfermedades inflamatorias y/o autoinmunes.
ES2544974T3 (es) Base, productos que contienen la misma, métodos de preparación y usos de los mismos
CL2009002201A1 (es) Procedimiento de sintesis de ivabradina por aminacion reductiva y posterior resolucion optica; y uno de los compuestos intermediarios considerados.
CR20120264A (es) Compuestos
DOP2010000178A (es) Peptidil nitrilos como inhibidores de dipeptidil peptidasa i
UY32062A (es) Inhibidores de beta-secretasa
HRP20120129T1 (en) Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists
ES2485825T3 (es) Intermedio de rosuvastatina cálcica y método de preparación del mismo
PE20141174A1 (es) Compuestos de pirrol como inhibidores de la bomba de protones
GEP20125512B (en) Process for synthesis of agomelatin
PA8840901A1 (es) Nuevo procedimiento de resolución de enantiómeros de (3,4-dimetoxi-biciclo[4.2.0]octa-1,3,5-trien-7-il, aplicación en la sistesis de ivabradina
MX2013006179A (es) Proceso para la preparacion de 2-metoximetil-1,4-bencenodiamina, sus derivados y sales de esta.
MY150280A (en) Process of preparing derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid
CL2011000296A1 (es) Proceso de preparación del ester metílico del ácido 4-oxo-octahidro-indol-1-carboxílico y compuestos intermediarios utilizados.
PT2462098E (pt) Processos para a preparação de derivados de ácido 1-(2- halobifenil-4-il)-ciclopropanocarboxílico
ES2529434T3 (es) Método para tratar neoplasias hematopoyéticas
UA106886C2 (uk) Спосіб одержання 1-бензил-3-гідроксиметил-1h-індазолу і його похідних та проміжні сполуки магнію
UY32042A (es) Compuestos de 2-aminopirimidina como potentes inhibidores de hsp-90
ME00927B (me) Novi postupak za sintezu agomelatina
AR077223A1 (es) Sales de fumarato de un antagonista del receptor de histamina h3